Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Myovant Sciences's share price for the quarter that ended in Dec. 2022 was $26.96. Myovant Sciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2022 was 97.0 Mil. Therefore, Myovant Sciences's market cap for the quarter that ended in Dec. 2022 was $2,615.9 Mil.
Myovant Sciences's quarterly market cap
increased
from Jun. 2022 ($1,189.0 Mil) to Sep. 2022 ($1,734.2 Mil) and
increased
from Sep. 2022 ($1,734.2 Mil) to Dec. 2022 ($2,615.9 Mil).
Myovant Sciences's annual market cap
increased
from Mar. 2020 ($678.2 Mil) to Mar. 2021 ($1,872.8 Mil) but then
declined
from Mar. 2021 ($1,872.8 Mil) to Mar. 2022 ($1,263.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Myovant Sciences's Enterprise Value for Today is $2,716.5 Mil.
Myovant Sciences Market Cap Historical Data
The historical data trend for Myovant Sciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Myovant Sciences's Market Cap
For the Biotechnology subindustry, Myovant Sciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myovant Sciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Market Cap falls into.
Myovant Sciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Myovant Sciences's Market Cap for the fiscal year that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Myovant Sciences Market Cap Related Terms
Thank you for viewing the detailed overview of Myovant Sciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Myovant Sciences (Myovant Sciences) Business Description
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MYOV has been successfully added to your 